This is an old revision of this page, as edited by TheCrimsonLegacy(talk | contribs) at 20:18, 25 November 2016(Added updated information regarding recent trials and FDA approval). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 20:18, 25 November 2016 by TheCrimsonLegacy(talk | contribs)(Added updated information regarding recent trials and FDA approval)
FORUM Pharmaceuticals, who currently is subjecting the drug to the FDA approval process, had all studies suspended until further notice in fall of 2015 due to rare, but serious gastrointestinal problems occurring in patients participating in the drug trial, potentially being a consequence of taking the drug. The trials were scheduled to be run until January 2017, but as of December 2016, they appear to still be on hold. There is speculation by FORUM Pharmaceuticals that this may be due to either the increased daily dose given in the Phase III trial compared to earlier trials that showed promise. In previous trials, the highest dose given was 2mg/day, with the most positive of effects having been realized in patients taking the largest dose (2mg/day). In the Phase III trial, all patients were treated with 3mg/day doses of the drug. FORUM also speculates that the increase of GI problems occurring in the phase III trial could be due to the increased demographic risk that elderly (the average age in the study was 75) and those with Alzheimer’s disease have in regards to Gastrointestinal issues, citing another study they conducted with a younger demographic (in which the average age was 35-40) for the treatment of schizophrenia of 1,500 individuals in which there were zero complains of GI problems. [3]
^Barbier, AJ (2015-02-01). "Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective α7 Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies". Clinical Therapeutics. 37 (2): 311–24. doi:10.1016/j.clinthera.2014.09.013. PMID25438724.
